All News

2020

October

Media Release / Oct 29, 2020

Novartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasis

Read More
Media Release / Oct 29, 2020

Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness

Read More
Media Release / Oct 28, 2020

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

Read More
A man riding his bike on the Novartis Basel Campus in autumn
Featured News / Oct 27, 2020

Novartis Financial Results – Q3 2020

Novartis announced the company’s financial results for the third quarter of 2020.

Read More
Media Release / Oct 27, 2020

Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.

Read More
Media Release / Oct 26, 2020

Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)

Read More
Media Release / Oct 23, 2020

Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)

Read More
Media Release / Oct 21, 2020

Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)

Read More
Media Release / Oct 16, 2020

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

Read More
Media Release / Oct 09, 2020

Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More